Board recommends name change to Nonprescription Drug Manufacturers Association (NDMA) to help better identify association with the industry it represents. President James Cope called current name "an impediment in presenting association views on key issues" and cited a 1978 survey showing that majority of public could not identify products/services represented by P-A. Proposed new name, one of "at least 75 considered," will be voted on at annual meeting in May.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.